Arcticzymes Technologies ASA (AZT)
Oslo Stock Exchange · Norway · prices in NOK · close of 23 Oct 2026
Key indicators
| Last close | NOK 20.30 |
|---|---|
| 52-week range | 18.30 – 30.50 |
| Return, 1 month / 3 months | −2.9% / +1.0% |
| Return, 1 year / 3 years | −31.0% / −21.9% |
| Trend | Below its 200-day average |
| RSI (14) | 54 |
| Volatility (1 year) | 47.9% |
| Worst drawdown (1 year) | -38.4% |
| Average daily value traded | 0.75M NOK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
ArcticZymes Technologies ASA is a biotechnology company based in Tromsø, Norway. It develops and produces enzymes derived from cold-adapted marine organisms found in Arctic waters. These enzymes are supplied to customers in molecular diagnostics, life science research and bioprocessing, where they are used in laboratory tests and manufacturing processes. The company also offers related products and services that support the handling and use of these enzymes in diagnostic and research settings.
On this site Arcticzymes Technologies ASA appears as a stock on the Oslo Stock Exchange (Norway), code AZT, with prices in Norwegian kroner (NOK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Arcticzymes Technologies ASA (AZT) trades on the Oslo Stock Exchange in Norway. It last closed at NOK 20.30 on 23 October 2026.
Its price-based Market X-Ray is 39 out of 100 (a weak price profile), ranking 205 of 294 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 31.0% and over the last three months it rose 1.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Oslo Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 40 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -1.8% | ||
| From 52-week high | -33.0% | ||
| Momentum | 42 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 1.0% | ||
| 6-month return | -1.9% | ||
| 12-month return, skipping the last month | -28.9% | ||
| Stability (higher is calmer) | 34 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 47.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -38.4% | ||
| Liquidity | 39 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.75M NOK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +3.8% |
|---|---|
| 1 month | −2.9% |
| 3 months | +1.0% |
| 6 months | −1.9% |
| 1 year | −31.0% |
| 3 years | −21.9% |
| 5 years | −75.4% |
Signals
| 50-day / 200-day average | 20.36 / 20.68 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.83 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Oslo Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.